LY3866288 for Healthy Subjects

Recruiting in Palo Alto (17 mi)

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Eli Lilly and Company

No Placebo Group

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to evaluate how much of the study drug (LY3866288), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy participants. The study will also measure how much of the study drug gets into the bloodstream when taken orally, compared to when injected directly into the vein, how its broken down, and how long it takes the body to get rid of it. The study will also evaluate the safety and tolerability of LY3866288.The study is conducted in two parts. The study is expected to last approximately 68 days.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for healthy men and women with a BMI between 18.0 and 32.0 kg/m^2, who pass medical exams including ECGs and lab tests. Men must be infertile (via surgery), while non-childbearing women must use contraception.

Inclusion Criteria

* Male and female participants who are overtly healthy determined by medical history, physical examination, 12-lead ECGs, vital signs measurements, and clinical laboratory evaluations at screening and/or check-in by the investigator * Have Body mass index between 18.0 and 32.0 kg/m\^2 (kilograms per meter squared)

I am a male and infertile due to having had surgery.

I am a woman not able to bear children and I use birth control.

Treatment Details

Interventions

[14C]-LY3866288 (Other)
LY3866288 (Other)

Trial Overview[14C]-LY3866288, a study drug marked with radioactive carbon (14C), is being tested to see how it's processed by the body when taken orally or injected into the vein—how much enters blood, urine, feces, air expelled from lungs, its breakdown and elimination time.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: Part B: LY3866288 + [14C]-LY3866288Experimental Treatment2 Interventions

Single dose of LY3866288 administered orally followed by a single dose of \[¹⁴C\]-LY3866288 administered intravenously (IV).

Group II: Part A: [14C]-LY3866288Experimental Treatment1 Intervention

Single dose of \[¹⁴C\]-LY3866288 administered orally.